The FDA has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease for patients 12 years of age and older, marking a significant step forward in the treatment of the disease.
The FDA has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease for patients 12 years of age and older, marking a significant step forward in the treatment of the disease.
Be the first to know: Stories from The Washington Informer in your inbox each weekday.
We'll send a verification code to %EMAIL%.
Get the best of The Washington Informer directly in your email inbox.
Sending to: